Leerink Partnrs Has Bullish Forecast for IDYA Q2 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities researchers at Leerink Partnrs raised their Q2 2025 earnings estimates for IDEAYA Biosciences in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.86) for the quarter, up from their prior forecast of ($0.92). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences' Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($3.83) EPS and FY2027 earnings at ($3.69) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.53) earnings per share.

IDYA has been the topic of several other research reports. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Finally, Stephens reaffirmed an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Price Performance

Shares of IDYA traded up $0.93 during midday trading on Friday, hitting $18.35. The stock had a trading volume of 1,381,056 shares, compared to its average volume of 991,823. The company has a 50 day simple moving average of $17.74 and a two-hundred day simple moving average of $22.59. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $44.42. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -5.56 and a beta of 0.26.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of IDYA. R Squared Ltd bought a new position in IDEAYA Biosciences during the fourth quarter worth about $35,000. CWM LLC grew its holdings in IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after purchasing an additional 1,814 shares during the period. PNC Financial Services Group Inc. grew its holdings in IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock worth $39,000 after purchasing an additional 1,546 shares during the period. GF Fund Management CO. LTD. bought a new position in IDEAYA Biosciences during the fourth quarter worth about $47,000. Finally, Signaturefd LLC grew its holdings in IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after purchasing an additional 2,271 shares during the period. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.